Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Thrombocytopenias in the U.S.

May 27, 2008
Revlimid (Celgene) in CLL- not a bad addition in our therapeutic algorithm
By a GLG Expert Contributor
Analysis of: Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia (bloodjournal.hematologylibrary.org)
Revlimid has activity in Chronic Lymphatic Leukemia (CLL) in addition to myeloma and myelodysplasia.
May 27, 2008
So much for non-invasive surgery in prostate cancer
By a GLG Expert Contributor
Analysis of: Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
Higher recurrance rate???!!!
May 27, 2008
Genentech, Schering-Plough,,Avant Immunotherapeutics. & Pfizer all helping with "brain cancer" therapy.
By a GLG Expert Contributor
Analysis of: Hints of Progress in Drugs Treating Brain Cancer (www.nytimes.com)
     While no slam dunk cures are noted, drugs such as Avastin (Genentech), Temodar (Schering-Plough) &  Avant/Pfizer  vaccines  are making an impact on  "Brain Cancer"  survival.
May 22, 2008
Erbitux: Alot remains to be determined re: its place in NSCLCA therapy
By a GLG Expert Contributor
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). (www.abstract.asco.org)
" Conclusions: Cetuximab does not appear to add to treatment efficacy when combined with gemcitabine and docetaxel in advanced NSCLC. A high rate of severe cetuximab HSRs necessitated trial closure at our Nashville site." Not very promising.
May 20, 2008
Chinese Generics?? You must be kidding!
By a GLG Expert Contributor
Analysis of: China Muscles In On The Generics Industry (www.pharmalot.com)
Low cost generics to be produced in China will lower drug costs.
May 20, 2008
Global Cancer Market: room for further growth!
By a GLG Expert Contributor
Analysis of: Global market expected to drive cancer drug growth (www.therapeuticsdaily.com)
As world economies improve more money will be spent globally on cancer care expanding potential markets
Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma (www.pipelinereview.com)
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem (www.sltrib.com)
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
Brian Abbott, MD, Medical Director of Hematology
Brian Abbott, MD, Medical Director of Hematology
Big Sky Oncology
May 19, 2008
Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting (www.redorbit.com)
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
May 19, 2008
The gods giveth and then takith away- Go figure.....
By a GLG Expert Contributor
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations (jco.ascopubs.org)
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next81 to 90 of 445

Analytics


Generated at 2009-01-07T13:00:17.563